A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor

Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare immunodeficiency disorder caused by gain-of-function mutations in the G protein–coupled chemokine receptor CXCR4. The CXCR4 antagonist plerixafor, which is approved by the US Food and Drug Administration (FDA) for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: McDermott, David H., Liu, Qian, Velez, Daniel, Lopez, Lizbeeth, Anaya-O’Brien, Sandra, Ulrick, Jean, Kwatemaa, Nana, Starling, Judy, Fleisher, Thomas A., Priel, Debra A. Long, Merideth, Melissa A., Giuntoli, Robert L., Evbuomwan, Moses O., Littel, Patricia, Marquesen, Martha M., Hilligoss, Dianne, DeCastro, Rosamma, Grimes, George J., Hwang, Samuel T., Pittaluga, Stefania, Calvo, Katherine R., Stratton, Pamela, Cowen, Edward W., Kuhns, Douglas B., Malech, Harry L., Murphy, Philip M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3983611/
https://ncbi.nlm.nih.gov/pubmed/24523241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-09-527226
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados